Latent TB Testing Market

The report "Latent TB Testing Market by Test Type (Tuberculin Skin Test/TST, IGRA Test), Application (Household Contacts (HHC) of Tuberculosis (TB) Patients, People Living with HIV), End User (Diagnostic Labs, Hospitals), Region - Global Forecast to 2029", is valued at an estimated USD 582.5 million in 2024 and is projected to reach USD 773.4 million by 2029 at a CAGR of 5.8% during the forecast period.

Browse 270 market data Tables and 46 Figures spread through 260 Pages and in-depth TOC on "Latent TB Testing Market by Test Type (Tuberculin Skin Test/TST, IGRA Test), Application (Household Contacts (HHC) of Tuberculosis (TB) Patients, People Living with HIV), End User (Diagnostic Labs, Hospitals), Region - Global Forecast to 2029"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/latent-tb-testing-market-125200332.html

The latent TB testing market is expanding due to the growing incidence of tuberculosis worldwide and the increasing need for early detection as well as preventive interventions. The traditional tuberculin skin tests have limitations, and the problem of false positives increases with the widespread use of BCG vaccination, which has fueled the increased use of more precise diagnostics such as interferon gamma release assays (IGRAs). This is coupled with the increasing TB elimination programs led by governments, public health initiatives, and the intensified further demand for adequate testing methods in high-burden countries. Increased awareness among healthcare providers and the increased risk groups, such as people living with immunodeficiency diseases, for example, individuals with HIV, increases the need for better diagnostics. Increased financial and regulatory support also makes these diagnostics more accessible to the general population. All these factors promote steady growth in the latent TB testing market.

In 2023, the people living with HIV segment dominated the latent TB testing market by application segment.

Based on application, the latent TB testing market is segmented into household contacts (hhc) with pulmonary tuberculosis (tb)/household contacts (hhc) of tuberculosis (tb) patients, people living with HIV, and other applications. The people living with HIV segment dominated the largest share of the global latent TB testing market in 2023.  People suffering from HIV have compromised immune systems and hence are at an extremely increased risk of infections caused by latent TB. Routine screening and early detection thus become crucial for them. Global health initiatives and strategic efforts are also being undertaken towards integrated care focused on TB testing among PLHIV. In this regard, identification of latent infections before these become active forms of TB prevents the further complications of resulting TB and reducing mortality rates. Additionally, new product launches, and regulatory approvals of advanced TB tests have created opportunities for testing and simplified the testing process and thus increased the usage of latent TB tests in this high-risk segment.

In 2023, the largest end-user segment of the latent TB testing market was diagnostic laboratories.

Categorized by end user, the latent TB testing market is segmented into diagnostic laboratories, hospitals & clinics, academic & research institutes, and other end users. The largest share of the latent TB testing market was held by the diagnostic laboratories segment in 2023. As the number of tuberculosis cases increases globally, diagnostic laboratories play a critical role in ensuring accurate results for the diagnostic tests, hence ensuring proper management and treatment of latent TB. With the implementation of quality control measures and standardized procedures in diagnostic laboratories, there will be a guarantee of the validity and accuracy of test results. Moreover, heightened awareness about the threat of latent TB, especially among specific vulnerable groups, has led to the increase in the number of tests undertaken at such centers. Therefore, these factors contribute to the dominance of diagnostic laboratories in the latent TB testing market.

North America is the largest regional market for latent TB testing market.

The market for latent TB testing has been divided into five key geographical regions, namely North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2023, North America held the predominant portion of the latent TB testing market. The latent TB testing market in North America is the biggest regional market, mainly due to several key factors, such as an established healthcare infrastructure across the region and the extensive availability of advanced diagnostic tools, like interferon gamma release assays, that are highly sensitive and convenient to use. Moreover, government initiatives and the control programs for TB prevailing in the US and Canada, which strongly emphasize on early detection and preventive care also stimulate the demand for latent TB tests. The increasing number of vulnerable populations, including the immunocompromised patients and healthcare providers, also increases the need for TB-specific diagnostics. Also, with more people being educated about prevention, along with a large surge in public health-related investments, North America is likely to remain a larger market.

The major players operating in this market are QIAGEN (Netherlands), Revvity (US), Beijing Wantai Biopharmaceutical Co., Ltd. (China), Sanofi (France), Endo, Inc. (US),  bioMérieux (France), SD Biosensor, INC. (South Korea), Lionex GmbH (Germany), Sanofi (France), Serum Institute of India Pvt. Ltd. (India), ARKRAY, Inc. (Japan), Zhi Fei Biological (China), AID Autoimmun Diagnostika GmbH (Germany), Boditech Med Inc. (South Korea), Bioneovan Co., Ltd (China), and Biopanda Reagents Ltd (UK).

Don’t miss out on business opportunities in Latent TB Testing Market. Speak to our analyst and gain crucial industry insights that will help your business grow.

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]